Paris, May 31, 2024 – Jeantet advised Pegase Healthcare, a strategy and communications consultancy firm that supports transformations in the healthcare sector, in LBO with Turenne Santé since 2022, on the acquisition of Com&Co, a Marseille-based player in medical training and conference organizer with sales of almost €10 million.

This external growth will enable the oncology strategy consulting group headed by Dimitri Verza to complement its therapeutic expertise and sectors.

“Com&Co provides an international scale to the group, and will benefit from the scientific aura of Pegase Healthcare”, say Paul Chamoulaud and Grégory Dupas, Associate Director and Investment Director at Turenne Santé, who also welcome the arrival of a young manager, Benjamin Richier, whose profile complements those at Pegase, alongside Dimitri Verza.

For the latter, who had opened up his capital to a minority shareholder in order to strengthen Pegase Health’s attractiveness in terms of recruiting new talent and acquiring companies, the objective is now to achieve sales of €30 million within four or five years, with an EBITDA of around 20%, excluding new external growth.

Pegase Healthcare, with its activities in strategic consulting, business intelligence/market access, communication, education and medical training, to support biotech, medtech and pharmaceutical companies throughout the lifecycle of the drug, in oncology as well as in the disease segment, has announced revenues of €12 million for the current financial year.

Com&Co is a key player in the field of medical information and training. Founded in 2003, the company organizes over 80 congresses a year in some 15 countries, and produces e-learning modules for professionals, drawing on its team of some 30 experts in events, digital, audiovisual and communications, with sales of almost €10 million.